BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Chronic lymphocytic leukemia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for chronic lymphocytic leukemia: 149 (67 sponsors; 9 newly posted in the last 180 days, 3 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 12.1, rank 57 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 37, Phase 2 49, Phase 3 34, Phase 4 5, N/A 23.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
BeOne Medicines ONC10P3 6, P2 401
Loxo Oncology, Inc.5P3 4, P2 100
AstraZeneca AZN17NA 9, P3 3, P2 4, P4 105
Acerta Pharma BV8P3 3, P2 3, P1 201
Merck Sharp & Dohme LLC MRK6P3 3, P2 310
AbbVie ABBV11P2 2, P1 4, P3 2, NA 301
Ascentage Pharma Group Inc. AAPG8P3 2, P1 4, P2 202
Janssen Research & Development, LLC6NA 1, P3 2, P2 1, P1 211
Nurix Therapeutics, Inc. NRIX5P1 2, P2 2, P3 101
Dizal Pharmaceuticals3P3 1, P2 200
BeiGene2P3 1, P2 100
Newave Pharmaceutical Inc2P1 1, P3 101
Beijing InnoCare Pharma Tech Co., Ltd.1P3 100
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. new entrant1P3 110
CSL Behring new entrant1P3 110
Grifols Biologicals, LLC GRFS1P3 100
Grifols Therapeutics LLC GRFS1P3 100
Eli Lilly and Company LLY4P2 1, P4 300
Genmab GMAB3P2 300
Ossium Health, Inc.3NA 2, P2 110
Bristol-Myers Squibb BMY2NA 1, P1 101
Guangzhou Lupeng Pharmaceutical Company LTD. new entrant2P2 220
iOMEDICO AG2NA 200
Miltenyi Biomedicine GmbH2P1 1, NA 100
Accutar Biotechnology Inc1P1 100

New-entrant sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSL Behring, Guangzhou Lupeng Pharmaceutical Company LTD..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Ascentage Pharma Group Inc. AAPGNCT05147467 Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLChronic Lymphocytic Leukemia; Small Lymphocytic Lymphomarecruiting75
2026-12-31 est.P3Janssen Research & Development, LLCNCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib)Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma;active not recruiting539
2026-12-31 est.P3Ascentage Pharma Group Inc. AAPGNCT06104566 Global Trial in APG2575 for Patients With CLL/SLLCLL/SLLrecruiting400

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2BeOne Medicines ONCNCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemiaactive not recruiting94
2026-11 est.P2AbbVie ABBVNCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring ChronicChronic Lymphocytic Leukemia (CLL)recruiting75
2026-10-28P2Genentech, Inc.NCT06524375 A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Chronic Lymphocytic Leukemiaactive not recruiting118
2026-10 est.P3Loxo Oncology, Inc.NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphomaactive not recruiting600
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12
2026-06-22 est.P2Cellectar Biosciences, Inc. CLRBNCT02952508 Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromWaldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymactive not recruiting120

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic lymphocytic leukemia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.